Skip to main content
SpringerLink
Log in

Docetaxel with or without zoledronic acid for castration-resistant prostate cancer

  • Urology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the efficacy and safety of zoledronic acid (ZA) in the combination of docetaxel-based chemotherapy for castration-resistant prostate cancer with bone metastases.

Methods

We conducted a prospective study in recruiting 105 prostate cancer patients with bone metastases from 2008 to 2010. Patients were randomly divided into two groups, 53 in the docetaxel-based chemotherapy + ZA(Group A) and 52 in the docetaxel-based chemotherapy + placebo(Group B). The different outcome between patients treated with chemotherapy combined with ZA and those with chemotherapy alone was evaluated. The Cox multivariate analyses of clinical features and different treatment methods of the 105 patients were conducted.

Results

There was a response of prostate-specific antigen (PSA) in 33 (62.3 %) in Group A and 28 (53.8 %) in Group B (P = 0.20). The combined approach group had better bone progression-free survival (BPFS) (9.0 vs. 6.0 months, P < 0.05) and overall survival (OS) (19.0 vs. 15.0 months, P = 0.02), but no statistical evidence of benefit was observed in terms of PSA response. Cox multivariate analysis identified the following independent prognostic factors: received ZA, high Hb level and more than 6 cycles of chemotherapy. There were no clinical relevant differences in the frequencies of adverse events between these two groups.

Conclusions

Zoledronic acid treatment combined with docetaxel-based chemotherapy could have a better bone pain control and improve BPFS and OS for prostate cancer patients with bone metastases. The PSA response and SREs rate are similar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Heidenreich A, Bolla M, Joniau S et al (2009) EAU guidelines on prostate cancer. Available at: http://www.uroweb.org/nc/professional-resources/guidelines

  2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300

    Article  PubMed  Google Scholar 

  3. Stephenson AJ, Kattan MW, Eastham JA et al (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27(26):4300–4305

    Article  PubMed Central  PubMed  Google Scholar 

  4. Alicikus ZA, Yamada Y, Zhang Z et al (2011) Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 117(7):1429–1437

    Article  PubMed  Google Scholar 

  5. Dai B, Ye DW, Kong YY, Shen YJ, Wang BH (2008) Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J Androl 10:325–331

    Article  PubMed  Google Scholar 

  6. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52(3):154–79. doi:10.3322/canjclin.52.3.154

  7. Diaz M, Patterson SG (2004) Management of androgen-independent prostate cancer. Cancer Control 11(6):364–373

    PubMed  Google Scholar 

  8. Kaufman JM, Johnell O, Abadie E, Adami S, Audran M, Avouac B, Sedrine WB, Calvo G, Devogelaer JP, Fuchs V, Kreutz G, Nilsson P, Pols H, Ringe J, Van Haelst L, Reginster JY (2000) Back-ground for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59(10):765–772

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. He J, Zeng ZC, Yang P, Chen B, Jiang W et al (2012) Clinical features and prognostic factors for patients with bone metastases from prostate cancer. Asian J Androl 14:505–508

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Major PP, Cook R (2002) Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 25(6 Suppl 1):S10–S18

    Article  PubMed  Google Scholar 

  11. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882

    Article  CAS  PubMed  Google Scholar 

  12. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468

    Article  CAS  PubMed  Google Scholar 

  13. Nayyar R, Sharma N, Gupta NP (2009 ) Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival. Int J Urol. 16(9):726–731. doi:10.1111/j.1442-2042.2009.02351.x

    Article  CAS  PubMed  Google Scholar 

  14. Qu YY, Dai B, Kong YY, Ye DW, Yao XD, Zhang SL, Zhang HL, Ma CG, Yang WY (2013) Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 15(1):110–115. doi:10.1038/aja.2012.110

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Tannock IF, Wit RD, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  16. Petrylak DP, Tangen CM, Maha PH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  CAS  PubMed  Google Scholar 

  17. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R (2004) Approval summary: docetaxel in combination with prednisone for the treatment of androgen independent hormone refractory prostate cancer. Clin Cancer Res 10:147–151

    Article  Google Scholar 

  18. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F (2007) Effects of skeletal morbidities on longitudinal patient reported outcomes and survival inpatients with metastatic prostate cancer. Support Care Cancer 15(7):869–876

    Article  PubMed  Google Scholar 

  19. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Reitsma D, Urbanowitz G, Seaman JJ (2003) Zoledronic acid versus placebo in them treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Clin Oncol 21(16):3150–3157

    Article  CAS  Google Scholar 

  20. Brubaker KD, Brown LG, Vessella RL, Corey E (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6:15

    Article  PubMed Central  PubMed  Google Scholar 

  21. Ullen A, Lennartsson L, Harmenberg U et al (2005) Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 44:644–650

    Article  CAS  PubMed  Google Scholar 

  22. Ural AU, Avcu F (2006) Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms? Acta Oncol 45:491–492

    Article  CAS  PubMed  Google Scholar 

  23. Sonpavde G, Pond GR, Berry WR, Wit RD, Armstrong AJ, Eisenberger MA, Tannock LF (2012) Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 30(5):607–613. doi:10.1016/j.urolonc.2010.07.002

  24. Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen—deprivation therapy for prostate cancer. N Engl J Med 345:948

    Article  CAS  PubMed  Google Scholar 

  25. Wang F, Chen W, Chen H, Mo L, Jin H, Yu Z, Li C, Liu Q, Duan F, Weng Z (2013) Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases. Med Oncol 30(3):657. doi:10.1007/s12032-013-0657-x

    Article  PubMed  Google Scholar 

  26. Schiavenato M, Craig KD (2010) Pain assessment as a social transaction: beyond the “gold standard”. Clin J Pain 26(8):667–676

    PubMed  Google Scholar 

  27. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26:2544–2549

    Article  PubMed  Google Scholar 

  28. Yee CH, Ng CF, Wong AY, Chan CK, Hou SM, Yip SK (2011) Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer. Asia Pac J Clin Oncol 7:168–173. doi:10.1111/j.1743-7563.2011.01388.x

    Article  PubMed  Google Scholar 

  29. Shamseddine A1, Farhat FS, Elias E, Khauli RB, Saleh A, Bulbul MA (2013) High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. Urol Int 90(1):56–61. doi:10.1159/000343780

  30. Sabry NA, Habib EE (2011) Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study. Med Oncol 28(2):584–590. doi:10.1007/s12032-010-9461-z

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by the Wenzhou science bureau project (Y20100023). We thank lecturer Fengsu. Yang for her generous help in manuscript revision. This work or part of results has not been published in any other journal or publication.

Conflict of interest

All authors state that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, People’s Republic of China

    Yue Pan, Haiyong Jin, Wei Chen, Zhixian Yu, Tingyu Ye, Yuancai Zheng, Zhiliang Weng & Feng Wang

Authors
  1. Yue Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haiyong Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhixian Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tingyu Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuancai Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhiliang Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Feng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhiliang Weng or Feng Wang.

Additional information

Yue Pan and Haiyong Jin have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pan, Y., Jin, H., Chen, W. et al. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. Int Urol Nephrol 46, 2319–2326 (2014). https://doi.org/10.1007/s11255-014-0824-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-014-0824-9

Keywords

Search

Navigation